Vivos Therapeutics, Inc. (VVOS) Analyst Estimates Annual - Discounting Cash Flows
VVOS
Vivos Therapeutics, Inc.
VVOS (NASDAQ)
Period Ending: 2026
12-31
2025
12-31
2024
12-31
2023
12-31
2022
12-31
2021
12-31
2020
12-31
Number of Analysts 1 1 1 1 1 1 1
Estimated Revenue
Low 23.1 15.2 14 12.88 16.28 17.3 12.94
Average 25.08 16.5 15.2 13.98 16.55 17.3 12.94
High 27.06 17.8 16.4 15.09 16.82 17.3 12.94
Estimated EBITDA
Low -24.7 -16.25 -14.97 -13.77 -15.9 -16.33 -12.22
Average -22.89 -15.06 -13.87 -12.76 -15.64 -16.33 -12.22
High -21.08 -13.87 -12.78 -11.75 -15.39 -16.33 -12.22
Estimated EBIT
Low -25.2 -16.58 -15.27 -14.05 -16.3 -16.75 -12.53
Average -23.36 -15.37 -14.16 -13.02 -16.04 -16.75 -12.53
High -21.51 -14.15 -13.04 -11.99 -15.78 -16.75 -12.53
Estimated Net Income
Low -7.44 -10.88 -11.18 -58.2 -33 -27.44 -18.29
Average -6.75 -9.86 -10.14 -52.78 -32.31 -27.44 -18.29
High -6.06 -8.85 -9.1 -47.37 -31.63 -27.44 -18.29
Estimated SGA Expenses
Low 39.35 25.88 23.85 21.93 28.76 30.56 22.86
Average 42.72 28.1 25.89 23.81 29.24 30.56 22.86
High 46.09 30.32 27.93 25.69 29.71 30.56 22.86
Estimated EPS
Low -1.48 -2.17 -2.23 -11.59 -27.06 -22.5 -15
Average -1.34 -1.97 -2.02 -10.52 -26.5 -22.5 -15
High -1.21 -1.76 -1.81 -9.44 -25.94 -22.5 -15
discounting cash flows home logo

Discounting Cash Flows

Are you finding our services helpful? Review us on trustpilot logo Trustpilot
Have a question? Contact us
Want to become our sponsor?
Check out our Affiliate Program